UPI (MM)

MINNEAPOLIS, Nov. 8, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today it will be presenting at the following investor conferences:  

Lazard Capital Markets 8th Annual Healthcare Conference

Date: Tuesday, November 15, 2011

Time: 9:00 a.m. ET

Location: New York, NY

Speaker: David Kaysen, President and CEO

Stephens Fall Investment Conference, New York

Date: Wednesday, November 16, 2011

Time: 11:30 a.m. ET

Location: New York, NY

Speaker: David Kaysen, President and CEO

Mr. Kaysen will review the company's business strategy and recent corporate developments. Uroplasty will offer live webcasts of both of its presentations on the Company's website www.uroplasty.com. An archived replay of the presentations will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

SOURCE Uroplasty, Inc.